Mark Trusheim
Senior Strategy Advisor, NEWDIGS Tufts Medical Center
Mark Trusheim is senior strategy advisor of NEWDIGS at Tufts Medical Center. Mark’s research focuses on the economics of biomedical innovation, especially payment innovations for biopharmaceuticals and gene therapies, biosimilars, and precision medicine. Mark held appointments for 18 years at MIT Sloan in applied economics and has served as a special government employee for the FDA’s Office of the Commissioner. Mark is also president of Co-Bio Consulting, LLC. His career has spanned policy as the president of the Massachusetts Biotechnology Council, diagnostics as founder of Cantata Labs, genomics as president of Cereon Genomics, eHealth as vice president of Monsanto Health Solutions, managed care marketing at Searle Pharmaceuticals, and big data at Kenan Systems. He holds degrees in chemistry from Stanford University and management from MIT.
Seminars
- Integrating cell and gene therapy development success rate and market projections to clarify future coverage, adoption and cost implications
- Mapping indication level differences to show why cell and gene therapies cannot be treated as a single market and where payer and patient dynamics diverge
- Highlighting how insurance and delivery system innovations could impact real-world cell and gene therapy uptake
- Examining how evolving clinical data, payer expectations and policy shifts are redefining commercial success for advanced therapies
- Understanding how affordability pressures, evidence requirements and real-world delivery constraints are shaping near term and long-term market viability
- Exploring what manufacturers, payers and providers need to prioritize to sustain patient access as pipelines expand into larger and more common indications
